louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03871010: Midline Programme - Vascular Nursing Team
Official title: Midline Programme - Vascular Nursing Team
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Inflammation
Local; Infection
Keywords: Midline catheter
Vascular nursing team
Lead sponsor: University Hospital Ostrava
Sponsor class: OTHER
First posted: 2019-03-12
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Midline catheter hospitalized at clinical department of the University Hospital Ostrava, Czech Republic

Brief summary: Integration of the Vascular Nursing Team of the Department of Haematooncology, University Hospital Ostrava for the needs of all clinical departments of the hospital. Assessment of local signs of inflammation in patients of the Department of Haematooncology and other clinical departments of the University Hospital Ostrava.

Detailed description: The study subjects were indicated by a physician for Midline catheter insertion.

Prior to insertion of the catheter, the study subjects were fully informed and signed the informed consent with participation in the study.

Local signs of inflammation were recorded in the study subjects, together with basic demographic characteristics (age, sex, diagnosis), and complications during catheter insertion, the number of days when the Midline catheter was inserted, number of changes of the dressings, presence of neutropenia in the study subjects and the score of local inflammation according to Madonna.

* Degree 0- no pain or reaction in the surrounding
* Degree 1 - pain only, no reaction in the surrounding
* Degree 2 - pain and reddening
* Degree 3 - pain, reddening, swelling or painful stripe along the vein
* Degree 4 - puss, swelling, reddening and painful stripe along the vein The investigators also observed on which day the first signs of infection appeared.

Eligibility criteria: Inclusion Criteria:

* insertion of Midline catheter by nurses from the Vascular Nursing Team
* age over 18 years

Exclusion Criteria:

- inability to insert the Midline catheter

Primary outcomes:
measure: Local signs of infection
timeFrame: 3 days at minimum
Secondary outcomes:
Other outcomes:
Locations:
city: Ostrava-Poruba
country: Czechia
facility: University Hospital Ostrava
state: Czech Republic
Study officials:
affiliation: University Hospital Ostrava
name: Kateřina Hašová, Mgr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06745310: Activities of Daily Living and Upper Extremity Exercise Capacity of Individuals with High Body Mass Index
Official title: Comparison of Activities of Daily Living and Upper Extremity Exercise Capacity of Individuals with High Body Mass Index with Those with Normal Body Mass Index
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Body Mass Index
Body Mass Index 25 or Greater
Body Mass Index, Normal
Lead sponsor: Kirsehir Ahi Evran Universitesi
Sponsor class: OTHER
First posted: 2024-12-20
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals with high and normal body mass index will be included in the study.

Brief summary: Individuals with high and normal body mass index will be included in this study.


Eligibility criteria: Inclusion Criteria for individuals with high body mass index:

* Body mass index ≥ 25 kg/m2
* Volunteering for the study

Exclusion Criteria for individuals with high body mass index:

* Having uncontrolled hypertension, diabetes mellitus
* Having comorbidities that may affect physical functions
* Failure to cooperate with tests to be performed
* Liver disease, kidney disease, cancer, lung diseases and serious cardiomyopathies, neurological diseases
* Pregnancy
* Having a history of bariatric surgery
* Presence of contraindications to exercise testing

Inclusion Criteria for individuals with normal body mass index:

* Body mass index 18.5-24.9 kg/m2
* Volunteering for the study

Exclusion Criteria for individuals with normal body mass index:

* Body mass index \> 25 kg/m2 or ≤18.5 kg/m2
* Having a known chronic or systemic disease
* Failure to cooperate with tests to be performed

Primary outcomes:
measure: Upper extremity exercise capacity
timeFrame: 1st day
measure: Daily living activities
timeFrame: 1st day
Secondary outcomes:
measure: Fatigue
timeFrame: 1st day
measure: Pain
timeFrame: 1st day
Other outcomes:
Locations:
city: Kirsehir
country: Turkey
facility: Kirsehir Ahi Evran University
Study officials:
References:
Clinical trial NCT06831110: Aquagenic Wrinkling Prediction
Official title: Using Aquagenic Wrinkling to Predict CF Carrier State
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Aquagenic Wrinkling of Palms
Carrier State
Lead sponsor: University of Iowa
Sponsor class: OTHER
First posted: 2025-02-17
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 24
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: University students

Brief summary: The goal of this observational study is to determine whether an aquagenic wrinkling procedure (i.e., soaking hands in a water bath for up to 20 minutes) can be used as a screening tool for cystic fibrosis carrier status.

Participants will complete one visit where they will undergo an aquagenic wrinkling procedure to see how their hands respond.


Eligibility criteria: Inclusion Criteria:

* Interested in participating in other CF Carrier-related research studies.

Exclusion Criteria:

* CF patient status
* Unable to speak English
* Unable to provide written informed consent
* Prisoner status
* An open wound on either hand
* A tattoo on either hand
* Missing any portion of either hand
* Diagnosis of Diabetes
* Diagnosis of Hyperhidrosis
* Diagnosis of Raynaud's Disease
* Diagnosis of Atopic Dermatitis
* Regularly taking ACE inhibitors or angiotensin receptor blockers

Primary outcomes:
measure: Human Observation of Wrinkling
timeFrame: Up to 20 minutes
measure: Machine-Learning Observation of Wrinkling
timeFrame: Up to 20 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
Study officials:
affiliation: University of Iowa
name: Philip M Polgreen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06151210: Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis
Official title: A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Gastritis Acute
Gastritis Chronic
Lead sponsor: Dong-A ST Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-11-30
Enrollment: 452
Sex: ALL
Minimum age (years): 19
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to evaluate the efficacy and safety of DA-5219 in patients with acute or chronic gastritis


Eligibility criteria: Main Inclusion Criteria:

* Men or women aged ≥ 19 years and ≤ 75 years
* Subjects who diagnosed with acute or chronic gastritis by upper gastrointestinal endoscopy within 7days prior to the randomization
* Subjects who have one or more erosions identified on upper gastrointestinal endoscopy within 7days prior to the randomization
* Subjects who voluntarily signed a consent form

Main Exclusion Criteria:

* Ineligible for upper gastrointestinal endoscopy
* Subjects with active or healing gastroduodenal ulcer, reflux esophagitis, Barrett's esophagus, or gastroesophageal varices identified on upper gastrointestinal endoscopy within 7days prior to the randomization
* Subjects with hypersensitivity to investigational drugs and similar drugs
* Pregnant or breastfeeding women

Primary outcomes:
measure: Improvement rate of gastric mucosal erosion
timeFrame: Change from baseline at 2 weeks
Secondary outcomes:
measure: Cure rate for gastric mucosal erosion
timeFrame: Change from baseline at 2 weeks
measure: Cure rate for gastric mucosal edema
timeFrame: Change from baseline at 2 weeks
measure: Improvement rate for gastric mucosal erythema
timeFrame: Change from baseline at 2 weeks
measure: Improvement rate for gastric mucosal bleeding
timeFrame: Change from baseline at 2 weeks
measure: Improvement rate for gastric subjective symptoms
timeFrame: Change from baseline at 2 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
References:
Clinical trial NCT04497610: SARS-CoV-2 (COVID-19) Detection Using the Breath Analizer TeraSystem
Official title: SARS-CoV-2 (COVID-19) Detection Using the Breath Analizer TeraSystem
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: COVID19
Keywords: SARS-CoV-2, coronavirus testing
Lead sponsor: Instituto Costarricense de Investigaciones Clínicas ICIC
Sponsor class: OTHER
First posted: 2020-08-04
Enrollment: 0
Sex: ALL
Minimum age (years): 7
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Population under Country's screening program and known positive cases.

Brief summary: The purpose of the study is to verify the sensibility and accuracy of a rapid detection test for SARS-CoV-2 in breath samples analyzed by the breath detector analyzer TeraSystem, comparing with PCR tests.

Detailed description: BioSafety Technologies has developed a rapid detection test to clear people of COVID-19.

A person can undergo an easy non-invasive test, to determine if they are: COVID-19 Clear (Negative) or Infected (Positive). The user-friendly process does not involve medically trained personnel.

The study will compare TeraSystem test results against PCR test results. Persons participating will be persons having a PCR test as part of the Health System and consenting to participate.

Eligibility criteria: Inclusion Criteria:

Older than 7 years odf age Able to provide informed consent Able to take the breath test

Exclusion Criteria:

Younger than 7 years of age Unable to provide informed consent Unable to take the breath test

Primary outcomes:
measure: Presence of disease
timeFrame: 1 minute
Secondary outcomes:
Other outcomes:
Locations:
city: San José
country: Costa Rica
facility: Instituto Costarricense de Investigaciones Clínicas
Study officials:
affiliation: Founder and Investigator
name: Guillermo Rodríguez Gómez, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01289210: VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
Official title: A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Low Grade B Cell Lymphoma
Keywords: B cell
lymphoma
Lead sponsor: Celgene
Sponsor class: INDUSTRY
Collaborators: name: Stanford University
First posted: 2011-02-03
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.


Eligibility criteria: Major Inclusion Criteria:

* low grade B cell lymphoma
* 1 or more sites of disease appropriate for intratumoral injection
* measurable disease other than the injection site
* Performance Status of 1 or better
* Adequate bone marrow, renal and hepatic function
* No active autoimmune disease or systemic immunosuppressive drugs
* Life expectancy \> 4 months

Exclusion Criteria:

* Known HIV
* Known brain metastases
* Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK)
* Anticoagulation therapy other than 325mg QD ASA
* Significant cardiovascular disease
* Pregnant or nursing

Primary outcomes:
measure: Number of Participants Whose Tumors Responded to Treatment With Intratumoral Injection of VTX-2337 in Combination With Low-Dose Local Radiation.
timeFrame: Tumor assessment conducted at 12 weeks and every 3-6 months thereafter
Secondary outcomes:
measure: Assess the Safety and Feasibility of the Combination Regimen.
timeFrame: Safety assessed throughout study period.
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford Cancer Center
state: California
Study officials:
affiliation: Celgene
name: Amar Patel, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06096610: Resistance Training in Children
Official title: The Effects of Resistance Training on Muscle Lipids in Children.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: exercise
muscle cross-sectional area
intramyocellular lipids
extramyocellular lipids
strength
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
Collaborators: name: National Strength and Conditioning Association
First posted: 2023-10-24
Enrollment: 3
Sex: ALL
Minimum age (years): 8
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The project is going to examine the effects of resistance exercise training in prepubescent youth on skeletal muscle strength and lipid content.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteer males and females ages 8 - 10 years.

Exclusion Criteria:

* No history or ongoing neuromuscular diseases.
* No history or ongoing musculoskeletal injuries.
* No history or ongoing disease that effects metabolism.

Primary outcomes:
measure: Change in the muscular strength of leg extensors, as measured with isotonic strength.
timeFrame: baseline, following the intervention (9 weeks)
Secondary outcomes:
measure: Change from baseline in thigh muscle cross-sectional area.
timeFrame: baseline, following the intervention (9 weeks)
Other outcomes:
measure: Change from baseline in intramyocellular lipids of the vastus lateralis, as measure with magnetic resonance spectroscopy
timeFrame: baseline, following the intervention (9 weeks)
measure: Change from baseline in extramyocellular lipids of the vastus lateralis, as measure with magnetic resonance spectroscopy
timeFrame: baseline, following the intervention (9 weeks)
measure: Change from baseline in the fatty acid saturation levels of the extramyocellular lipids of the vastus lateralis, as measure with magnetic resonance spectroscopy
timeFrame: baseline, following the intervention (9 weeks)
measure: Change from baseline in the fatty acid saturation levels of the intramyocellular lipids of the vastus lateralis, as measure with magnetic resonance spectroscopy
timeFrame: baseline, following the intervention (9 weeks)
Locations:
city: Kansas City
country: United States
facility: Hoglund Biomedical Imaging Center
state: Kansas
city: Overland Park
country: United States
facility: Exercise and Human Performance Laboratory
state: Kansas
city: Overland Park
country: United States
facility: Metabolic and Body Composition Laboratory
state: Kansas
Study officials:
References:
Clinical trial NCT06547710: Primary Tumor Resection for M1a Stage Lung Cancer
Official title: Primary Tumor Resection for M1a Stage Lung Cancer With Occult Pleural Dissemination Discovered During Surgery: a Prospective, Single-arm, Multi-center, Phase Ⅱ Trial
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lung Cancer Metastatic
Surgical Resection
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2024-08-09
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This clinical trial is a single-arm, multicenter, prospective, confirmatory phase II clinical study, which mainly evaluates the efficacy and safety of primary lesion resection for patients with M1a stage lung cancer who have occult pleural dissemination during surgery (Figure 1). Since it is unethical not to perform primary lesion resection during surgery for such patients, this study is a single-arm one. Primary lesion resection should be a resection that can completely remove the primary lesion, including lobectomy and sublobar resection.

Brief summary: This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1023. This study aims to explore the safety and efficacy of primary lesion resection in the treatment of M1a stage lung cancer with pleural dissemination found during surgery, and to more accurately evaluate whether primary lesion resection can improve the OS and quality of life of the corresponding patients.


Eligibility criteria: Inclusion Criteria:

1. Volunteer to participate in clinical research, willing to follow and able to complete all trial procedures;
2. Aged 18-80 years (including critical values) when signing the informed consent form;
3. ECOG score 0 or 1;
4. No previous lung cancer surgery;
5. Intraoperative or postoperative pathological confirmation of M1a stage lung cancer;
6. Occult pleural metastasis found during surgery;
7. Preoperative lymph node staging is cN0;
8. First-time treatment and no radiotherapy or chemotherapy.

Exclusion Criteria:

1. The lesion cannot be completely removed surgically;
2. Cytological or histological pathology confirms other lung malignancies other than lung cancer;
3. Patients who have undergone lung cancer surgery before;
4. Patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.

Primary outcomes:
measure: Median overall survival
timeFrame: About 10months.
Secondary outcomes:
measure: 2-year overall survival
timeFrame: 2 years
measure: 5-year overall survival
timeFrame: 5 years
measure: FEV1 and FVC
timeFrame: 0.5 year
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Cancer Center
state: Shanghai
Study officials:
References:
Clinical trial NCT02786810: Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy
Official title: Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Urinary Tract Infection
Vesicoureteral Reflux
Lead sponsor: University of Tennessee
Sponsor class: OTHER
First posted: 2016-06-01
Enrollment: 10
Sex: ALL
Minimum age (years): 8
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The study will be evaluating the efficacy and safety of a contrast drug in pediatric renal ultrasound.


Eligibility criteria: Inclusion Criteria:

* Informed consent
* Age more than or equal to 8 years
* Patient with history of urinary tract infection (UTI) and history of Voiding Cystourethrogram (VCUG) for vesicoureteral reflux
* Candidate for Dimercaptosuccinic acid (DMSA) scan or scan for renal scar
* Demonstration of renal scarring by DMSA scan or renal ultrasound without contrast

Includes healthy volunteers

Exclusion Criteria:

* Age less than 8years
* Allergy to contrast or related products
* Cardiac shunt/ congenital heart anomalies
* Abnormal baseline ECG
* Open heart surgery
* Evidence of retinopathy
* Patient in intensive care
* Unable to comply with study requirement
* History of emphysema
* Unable to maintain oxygen saturation of 92% on at room air
* Pregnancy and lactation

Primary outcomes:
measure: Visualization of Renal Scars Compared to Previous Imaging
timeFrame: 1 hour
Secondary outcomes:
measure: Number of Participants With Adverse Events Related to the Study Drug.
timeFrame: 1 week
Other outcomes:
Locations:
city: Memphis
country: United States
facility: University of Tennessee Health Science Center
state: Tennessee
Study officials:
affiliation: University of Tennessee
name: David Hains, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02541110: Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
Official title: Second Trimester Maternal Serum Homocysteine Level & Uterine Artery Doppler for Prediction of Preeclampsia , Intra-Uterine Growth Retardation (IUGR) & Other Obstetric Complications
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Preeclampsia
IUGR
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
First posted: 2015-09-04
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Spontaneous pregnancies with no risk factors

Brief summary: Second trimester homocysteine \& uterine artery doppler will be assessed\& the cases will be followed up till delivery for development of preeclampsia, IUGR(intra-uterine growth retardation) \& other obstetric complications.

Detailed description: Spontaneous pregnancies with no risk factors will be included. Fasting plasma total homocysteine level samples will be collected between 15th \& 19th weeks.

Uterine artery doppler between 18th \& 22nd weeks.

Method 1: Screen positive cases will be considered if homocysteine level above 6.3umol/l

Method 2: Screen positive cases will be considered if they had bilateral notches and a mean resistivity index (RI) above 0.55, or unilateral notches and a mean RI above 0.65, or absence of notches and a mean RI above 0.7.

Method 3: Screen positive cases will be considered if they had bilateral notches and a mean RI above 0.55, or unilateral notches and a mean RI above 0.65, or absence of notches and a mean RI above 0.7 combined with homocysteine cut off value of 6.3umol / l.

Eligibility criteria: Inclusion Criteria:

* spontaneous pregnancies with no risk factors

Exclusion Criteria:

* multiple pregnancies
* non intact renal function
* hypertension
* diabetes
* folic acid supplements
* antifolate drugs

Primary outcomes:
measure: Number of pregnants who developed preeclampsia, those who developed IUGR alone and those who developed other obstetric complications as preterm labour and placental abruption
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: kasrelaini hospital
name: suzy abdelaziz, M.D.
role: PRINCIPAL_INVESTIGATOR
References: